Noninvasive monitoring of therapy-induced microvascular changes in a XXXX model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent.

@entity1 @entity788 @entity2240 @entity5 @entity19 @entity7241 @entity136 @entity71905
A predictive technique in the management of @entity1 with @entity5 could improve the therapeutic index by allowing better individualization of treatment. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a noninvasive technique that can provide anatomical and physiological information on the @entity5 and its microenvironment. We studied the effect of chemotherapy ( @entity136 ), anti-angiogenesis therapy ( @entity2240 ) and radiotherapy on the kinetics of DCE-MRI parameters in a preclinical model of @entity788 using P846, a new low-diffusible contrast agent. @entity19 underwent DCE-MRI before treatment ( @entity71905 ), after 1 week of treatment (MRI2), and after 1 additional week (MRI3). Combined treatment with radiotherapy and @entity2240 had a synergistic effect on @entity5 growth. In radiotherapy/ @entity2240 -treated @entity19 , a decrease in K(trans) at MRI2 predicted its superior antivascular and antitumor effect at an early time. An increased K(trans) at MRI2, as seen in @entity136 - and @entity136 / @entity2240 -treated @entity19 , reflects increased permeability for P846 and might predict a smaller therapeutic effect at this early time. This study shows that the kinetics of DCE-MRI parameters depends on the contrast agent used. P846 appears to be a promising low-diffusible agent to monitor therapeutic effects in this preclinical @entity5 model, but further studies are needed to compare its behavior with @entity7241 and macromolecular-weight contrast agents. @entity2240 as a radiosensitizer is promising for future clinical trials in @entity1 @entity788 .
